XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Product and Geographic Sales Information
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Product and Geographic Sales Information Segment Information
The Chief Executive Officer is the Company’s Chief Operating Decision Maker (“CODM”). Prior to the fourth quarter of 2020, the Company’s CODM previously assessed the Company-wide performance and allocated resources based on consolidated financial information. During the fourth quarter of 2020, in connection with the CPA Global combination, the company realigned its reporting structure and changed the manner in which the CODM allocates resources and assesses performance. The CODM organizes the Company within products lines and, as a result, two new operating segments were created including the Science Group and Intellectual Property Group. The segment reporting changes were retrospectively applied to all periods presented. The CODM evaluates segment performance based primarily on revenue and segment Adjusted EBITDA, as described below. The CODM does not review assets by operating segment for the purposes of assessing performance or allocated resources.
Each of the Company’s reportable segments, Science Group and Intellectual Property Group, recognizes revenue in accordance with the revenue recognition policy within Note 3 - Summary of Significant Accounting Policies. Below is the overview of the product lines within each reportable segment.

Science: The Science segment consists of our Academic and Life Sciences Product Lines. Both provide curated, high-value, structured information that is delivered and embedded into the workflows of our customers, which include research-intensive corporations, life science organizations and universities world-wide.

Intellectual Property: The Intellectual Property segment consists of our Patent, Trademark, Domain, and IP Management Product Lines. These Product Lines help manage customer’s end-to-end portfolio of intellectual property from patents to trademarks to corporate website domains.

Each of the two operating segments represent the segments for which discrete financial information is available and upon which operating results are regularly evaluated by the CODM in order to assess performance and allocate resources. The CODM evaluates performance based primarily on revenue and segment Adjusted EBITDA. Adjusted EBITDA represents net (loss) income before provision for income taxes, depreciation and amortization, interest income and expense adjusted to exclude acquisition or disposal-related transaction costs (such costs include net income from continuing operations before provision for income taxes, depreciation and amortization and interest income and expense from divestitures), losses on extinguishment of debt, stock-based compensation, unrealized foreign currency gains/(losses), costs associated with the transition services agreement with Thomson Reuters, separation and integration costs, transformational and restructuring expenses, acquisition-related adjustments to deferred revenues, costs related to our merger with Churchill Capital Corp in 2019, non-cash income/(loss) on equity and cost method investments, non-operating income or expense, the impact of certain non-cash, legal settlements and other items that are included in net income for the period that the Company does not consider indicative of its ongoing operating performance and certain unusual items impacting results in a particular period.

The following table summarizes revenue by reportable segment for the periods indicated:
Three Months Ended March 31,
20212020
Science Segment$191,288 $145,694 
Intellectual Property Segment
237,142 94,898 
Total Revenues$428,430 $240,592 
Adjusted EBITDA by segment
The following table presents segment profitability and a reconciliation to net income for the periods indicated:
Three Months Ended March 31,
20212020
(As Restated)
Science Segment Adjusted EBITDA
$90,594 $63,954 
Intellectual Property Segment Adjusted EBITDA
74,239 14,268 
Total Adjusted EBITDA
$164,833 $78,222 
Benefit (provision) for income taxes
(3,569)(14,753)
Depreciation and amortization
(131,654)(51,441)
Interest, net
(37,393)(30,940)
Transition services agreement costs
— (1,551)
Transition, transformation and integration expense
(46)(2,228)
Deferred revenues adjustment
(3,024)(1,882)
Transaction related costs
26,639 (26,689)
Share-based compensation expense
(10,660)(17,469)
Restructuring and impairment
(64,667)(7,754)
Mark to market adjustment on financial instruments51,215 (55,632)
Other
(15,628)2,484 
Net income attributable to Clarivate
$(23,954)$(129,633)